A pilot study on acupuncture for lower urinary tract symptoms related to chronic prostatitis/chronic pelvic pain
© Capodice et al; licensee BioMed Central Ltd. 2007
Received: 05 June 2006
Accepted: 06 February 2007
Published: 06 February 2007
The etiology and treatment of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) remain poorly understood. Pain, lower urinary tract voiding symptoms and negative impact on quality of life (QOL) are the most common complaints. Acupuncture, which has been widely used to treat painful and chronic conditions, may be a potential treatment to alleviate the constellation of symptoms experienced by men with CP/CPPS. The purpose of our study was to assess the impact of standardized full body and auricular acupuncture in men refractory to conventional therapies and collect pilot data to warrant further randomized trials.
Ten men diagnosed with category IIIA or IIIB CP/CPPS >6 months, refractory to at least 1 conventional therapy (antibiotics, anti-inflammatory agents, 5-α reductase inhibitors, α-1 blockers) and scoring >4 on the pain subset of the NIH-CPSI were prospectively analyzed in an Institutional Review Board (IRB) approved, single-center clinical trial (Columbia University Medical Center IRB#AAAA-7460). Standardized full body and auricular acupuncture treatment was given twice weekly for 6 weeks. The primary endpoints were total score of the NIH-CPSI and assessment of serious adverse events. The secondary endpoints were individual scores of the NIH-CPSI and QOL questionnaire scores of the short-form 36 (SF-36).
The median age of the subjects was 36 years (range 29–63). Decreases in total NIH-CPSI scores (mean ± SD) after 3 and 6 weeks from baseline (25.1 ± 6.6) were 17.6 ± 5.7 (P < 0.006) and 8.8 ± 6.2 (P < 0.006) respectively and remained significant after an additional 6 weeks of follow-up (P < 0.006). Symptom and QOL/NIH-CPSI sub-scores were also significant (P < 0.002 and P < 0.002 respectively). Significance in 6 of 8 categories of the SF-36 including bodily pain (P < 0.002) was achieved. One regression in the SF-36 vitality category was observed after follow-up. There were no adverse events.
The preliminary findings, although limited, suggest the potential therapeutic role of acupuncture in the treatment of CP/CPPS. Data from this and previous studies warrant randomized trials of acupuncture for CP/CPPS and particular attention towards acupuncture point selection, treatment intervention, and durability of acupuncture.
The etiology for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) has not been fully elucidated and the current treatment strategies for CP/CPPS are not universally accepted . Chronic infection, inflammation, neuropathy, pelvic floor muscle dysfunction, autoimmune disease and neurobehavioral disorders are some of the postulated etiologies though no single factor is thought to be the absolute cause. Standard therapies for CP/CPPS include antibiotics, anti-inflammatory agents, 5-α reductase inhibitors, and α-1 blockers [1–3]. Recently, a multi-modal treatment approach and the utilization of complementary and alternative medicine (CAM) strategies such as acupuncture and phytotherapy have also been suggested as potential treatment options for CP/CPPS [4–7].
Acupuncture which has been used to treat painful and chronic conditions [8, 9] may be useful in the treatment of pain, urinary and quality of life (QOL) symptoms frequently seen in men with CP/CPPS. While the etiology, treatment, long-term effects on QOL and CP/CPPS as a predictor of future prostate disease are yet to be determined, the rationale for safe and effective treatment practices for this complex condition is needed. This pilot study was implemented in order to test the efficacy of full body and auricular acupuncture on pain, urinary and QOL symptoms related to CP/CPPS and inform future research and randomized clinical trials of acupuncture for the management of symptoms related to CP/CPPS.
Our target sample size was 10 men diagnosed with CP/CPPS who were also refractory to conventional therapies. Subjects being treated at or referred to the Department of Urology, Columbia University Medical Center between April and September 2005 were offered participation in the study (Columbia University Medical Center, Institutional Review Board approved, IRB# AAAA-7460). The Department of Urology, Columbia University Medical Center, is located in New York (New York, USA) and has a large, diverse patient population. The inclusion criteria were men between the ages of 18 and 65, previous diagnosis with category IIIA or IIIB chronic prostatitis for >6 months, refractory to at least 1 conventional therapy (antibiotics, anti-inflammatory agents, 5-α reductase inhibitors or α-1 blockers), scoring >4 on the pain subset of the NIH-CPSI, and able to read and sign the informed consent.
Exclusion criteria were prostate cancer, bladder cancer, testicular cancer, stone disease, neurogenic bladder dysfunction, interstitial cystitis, urethritis, active sexually transmitted diseases (chlamydia, gonorrhea, syphilis, active herpes simplex virus) active urinary tract infection, bleeding disorders, skin infection, chronic use of anti-inflammatory agents (defined as use >2 times per week), active use of phytotherapeutic agents (saw palmetto, cernilton, quercetin) and previous acupuncture treatment within the past 6 months.
The subjects enrolled in the study completed the standardized National Institute of Health chronic prostatitis symptom index (NIH-CPSI) at baseline (0 week), midpoint (3 weeks), endpoint (6 weeks) and follow-up (12 weeks).
Short-form 36 (SF-36)
The subjects enrolled in the study completed the standardized short-form 36 (SF-36) at baseline (0 week), midpoint (3 weeks), endpoint (6 weeks) and follow-up (12 weeks).
All investigators except ZJ (statistician) were blinded to the questionnaire answers and study results until completion of the study.
Sample size and statistical analysis
We determined our sample size based on previous studies [6, 7] and determination of treatment effect with a maximum allowable difference of 0.1 and confidence level of 95% of our primary outcome measure, i.e. the NIH-CPSI.
Each of the measures was summarized by mean ± standard deviation at each measurement week (0, 3, 6, 12). The changes of symptom measures at weeks 3, 6 and 12 compared to baseline (0 week) were assessed by the paired Wilcoxon signed test. P-values less than 0.05 are considered significant. All statistical analyses were carried out with the statistical software package SAS version 9.1.
Of 14 men screened for the study, 10 fit the inclusion/exclusion criteria and were enrolled into the study following informed consent. The median age of the 10 subjects was 36 years (range 29 to 63). The previous use of conventional therapies, i.e. antibiotics, non-steroidal anti-inflammatory drugs, 5-α reductase inhibitors and α-1 blockers, was as follows: antibiotics (quinilones: levofloxacin or ciprofloxacin) 10 of 10, non-steroidal anti-inflammatory drugs (ibuprofen, naproxen, cyclooxygenase-2 inhibitors) 6 of 10, and 5-α reductase inhibitors (finasteride) 3 of 10, and α-1 blockers (terazosin) 1 of 10. All 10 patients completed the study period and assessments at the scheduled time except for the 6-week follow-up (median 6 weeks, range 5.5–7.1).
Mean (SD) summary statistics of the NIH-CPSI score in 10 patients.
3 wk vs. 0
6 wk vs. 0
12 wk vs. 0
Symptom score = Pain + Urinary
Mean (SD) summary statistics of SF-36 QOL in 10 patients.
3 wk vs. 0
6 wk vs. 0
12 wk vs. 0
Role limitation due to physical health
Role limitation due to emotional problems
Though the etiology of CP/CPPS remains poorly understood, the gold standard of treatment is the use of fluroquinilones as first-line therapy [1–3]. Meanwhile, the application of self-reported NIH-CPSI implemented in 1999 by the Chronic Prostatitis Collaborative Research Network (CPCRN) is useful in determining the primary subjective patient symptoms [13–15]. This questionnaire has demonstrated a capacity in capturing the qualitative symptoms of men with CP/CPPS .
The data in our study demonstrate the safety of acupuncture and a significant treatment effect on the overall and individual pain, urinary and QOL symptoms as measured by administration of the NIH-CPSI following acupuncture treatment (2 times per week over 6 weeks). While absolute efficacy endpoints can not be established based on our uncontrolled study, trends regarding specific acupuncture application and treatment effects related to duration of treatment were noted in our study. The significant reduction in pain sub-scores of the NIH-CPSI following 3 weeks of treatment versus significant reduction in urinary sub-scores only after 6 weeks of treatment implies that the treatment effect of acupuncture for pain is quicker acting than it may be for urinary symptoms. The effect of acupuncture on pain was further supported by decreased scores in the bodily pain category of the SF-36, which were also significant after 3 weeks of treatment.
Quality of life
Emotional health and QOL with regard to social and sexual functioning has been observed in past studies of chronic prostatitis and co-morbid depression has also been postulated as a potential factor in the etiology of CP/CPPS [16, 17]. Interestingly, while none of our study patients were on any current anti-depressant medications, further analysis of the SF-36 revealed a significant change in role limitations due to emotional problems versus a non-significant change in mental health sub-component (following 3 and 6 weeks of treatment). Although a full mental health profile was not assessed in our study, these results are consistent with the hypothesis that chronic prostatitis may cause significant social and sexual distress but may not be related to co-morbid depression [18, 19].
Brief characteristics of the three acupuncture studies for CP/CPPS.
Chen et al. 2003
n = 12
Set 1: BL10,23,28,40, KI 10 K1, BL67-Bilateral
Set 2: CV3, 4, M-CA-17, SP 6 + 5 hz e-stim
Set 3: B:23, BL54, BL35
Three sets of points given alternately twice/week over 6 weeks. 20 minute treatment*
Honjo et al. 2004
n = 10
Single point applied bilaterally over 4 weeks. 10 minute treatment*
yes CPSI and IPSS
Capodice et al. 2007
n = 10
GB 41, LR 3, LI 4, SJ 5, SP 8, SP 6-Bilateral Shen men, kidney, liver, lung, spleen and one auricle
Twice/week full body and auricular acupuncture over 6 weeks. 20–25 minute treatment (needles in situ)+
Traditional functions of acupuncture points*.
San Jiao 5 (Triple Burner 5) – Wai guan
Frees the channels and quickens the connecting vessels, clears heat and resolves toxin, dissipates wind; Luo point of the san jiao channel, confluence point of the 8 extraordinary channels
Gall Bladder 41-Zulin qi
Courses liver and gallbladder qi stagnation, clears fire and extinguishes wind, transforms obstructing phlegm-heat; Shu point, confluence point of the 8 extraordinary channels
Liver 3-Tai chong
Extinguishes liver fire, clears liver yang, discharges damp-heat in the lower burner, soothes liver qi, frees the channels and quickens the connecting vessels; Shu point, yuan source point
Large Intestine 4-He gu
Frees the channels and quickens the connecting vessels, relieves pain and quiets the spirit; Yuan source point
Spleen 8-Di ji
Harmonizes the spleen and rectifies blood; Xi-cleft point
Spleen 6-San yin jiao
Supplements spleen, helps movement and transformation, frees qi stagnation, courses the lower burner; Intersection point of spleen channel, one of nine needles for returning yang
Promotes relaxation, relieves pain
Strengthens the kidneys
Strengthens gastrointestinal tract, relieves muscle spasms
Strengthens the gastrointestinal tract, strengthens following a disease
While these data suggest that acupuncture is beneficial for symptoms related to CP/CPPS, a number of research methodological issues, to be addressed in future studies, were present in the current study. These include selection of appropriate and homogenous treatment groups with regard to CP/CPPS such as duration of condition (e.g. >6 months to upwards of 20 years), previous and current biomedical treatment(s) and refractory status. Issues concerning acupuncture include high expectation of acupuncture for refractory patients, utilization of an appropriate, inert sham-control, acupuncture point selection and application of points within or independent of a traditional medicine framework.
Potential physiologic mechanisms of action
Research on the hypothesized mechanism of action of acupuncture for CP/CPPS reveals challenges in both CP/CPPS research and acupuncture research. As aforementioned, the exact etiology of CP/CPPS is not understood and no single treatment strategy has been deemed effective. Moreover, the exact mechanism of action of acupuncture is not clear. Regarding the use of acupuncture for CP/CPPS, the mechanism of action suggested in one of the previous studies implies a neuropathic etiology of CP/CPPS and suggests that one of the treatment effects of acupuncture is of a neuro-physiological nature .
While we agree that the hypothesis of a neuropathic model seems plausible, elucidating the exact physiological mechanisms of acupuncture for CP/CPPS may ultimately equally demand determination of the exact pathology of CP/CPPS including the discovery of new surrogate endpoints, biomarkers, and neuromodulatory mediators involved in inflammation, endocrine function and their implication in CP/CPPS pathology. We also hypothesize that acupuncture may have a multi-modal treatment effect(s) which may include pain relief via potential anti-inflammatory and neuromodulatory mechanisms as well as positive impact on QOL potentially involving non-specific effects of acupuncture such as patient-practitioner interaction. These new theories begin to introduce a biopsychosocial model and mechanism of CP/CPPS in diagnostic and treatment strategies and may be useful in future CP/CPPS studies of acupuncture and other new treatments [20–25].
Limitations of this study include small sample size, non-randomized, non-sham controlled trial design, possible placebo effect and investigators' bias that may exaggerate the findings of the study.
In addition, acupuncture was tested in a group of refractory patients. A recent study testing the use of ciprofloxacin, tamsulosin or both in refractory CP/CPPS men showed no clinical effect in any category, and concern regarding investigation of agents in previous treatment failures is notable . Recently, the Chronic Prostatitis Collaborative Research Network  and Habmermacher et al.  have proposed a treatment algorithm for newly diagnosed CP/CPPS patients dependent on subjective symptoms and a few clinical trials. This algorithm suggests the application of first to third-line medications and therapies depending on most acute symptoms and historical treatment outcomes for each related symptom . Therefore, the study of acupuncture as a potential first-line therapy or as an adjuvant therapy depending on primary patient who reported subjective symptoms may be of interest in our future studies. In addition, the complexity and controversy surrounding the design of an appropriate placebo for acupuncture research need to be addressed. Taken together, these challenges facing both conventional and non-conventional treatment options for CP/CPPS may generate greater understanding and a successful treatment for men with CP/CPPS.
The preliminary findings of this pilot study suggest a significant and safe treatment effect by acupuncture as measured by a validated questionnaire, for pain and lower urinary tract symptoms experienced by men with CP/CPPS. Data from this and previous studies warrant randomized trials of acupuncture for CP/CPPS in order to investigate the mechanism of action of acupuncture in CP/CPPS, via rigorous clinical trial design that may begin to address the complexity of acupuncture research including rationales for acupuncture point selection, treatment duration, and the ability to determine the effectiveness and durability of acupuncture in larger, randomized and multi-center trials.
Complementary and alternative medicine
Chronic prostatitis/chronic pelvic pain syndrome
National Institute of Health chronic prostatitis symptom index
Quality of life
- Kreiger JN, Ross SO, Penson DF, Riley DE: Symptoms and inflammation in chronic prostatitis/chronic pelvic pain syndrome. Urology. 2002, 60: 959-963. 10.1016/S0090-4295(02)01963-5.View Article
- Nickel JC: The three As of chronic prostatitis therapy: antibiotics, alpha-blockers and anti-inflammatories. What is the evidence?. BJU Int. 2004, 94: 1230-1233. 10.1111/j.1464-410X.2004.05148.x.View ArticlePubMed
- Pontari MA, Ruggieri MR: Mechanisms in prostatitis/chronic pelvic pain syndrome. J Urol. 2004, 172: 839-845. 10.1097/01.ju.0000136002.76898.04.PubMed CentralView ArticlePubMed
- Shoskes DA: Phytotherapy and other alternative forms of care for the patient with prostatitis. Curr Urol Rep. 2002, 3 (4): 330-4.View ArticlePubMed
- Potts JM: Therapeutic options for chronic prostatitis/chronic pelvic pain syndrome. Curr Urol Rep. 2005, 6 (4): 313-7.View ArticlePubMed
- Chen R, Nickel JC: Acupuncture ameliorates symptoms in men with chronic prostatitis/chronic pelvic pain syndrome. Urology. 2003, 61: 1156-1159. 10.1016/S0090-4295(03)00141-9.View ArticlePubMed
- Honjo H, Kamoi K, Naya Y, Ukimura O, Kojima M, Kitakoji H, Miki T: Effects of acupuncture for chronic pelvic pain syndrome with intrapelvic venous congestion: preliminary results. Int J Urol. 2004, 11: 607-612. 10.1111/j.1442-2042.2004.00868.x.View ArticlePubMed
- Audette JF, Ryan AH: The role of acupuncture in pain management. Phys Med Rehabil Clin N Am. 2004, 15: 749-772.View ArticlePubMed
- National Center for Complementary and Alternative Medicine website. Accessed on June 30, 2006, [http://nccam.nih.gov]
- Chen X, (ed): Chinese Acupuncture and Moxibustion. 1999, Foreign Languages Press, Beijing, China
- Wu Y, Fisher W: Practical Therapeutics of Traditional Chinese Medicine. 1997, Paradigm Publications, Brookline, MA
- Huang LC: Auriculotherapy diagnosis and treatment. 1997, Longevity Press, Bellaire, TX, 1-47.
- Litwin MS: A review of the development and validation of the National Institutes of Health Chronic Prostatitis Symptom Index. Urology. 2002, 60: 14-18. 10.1016/S0090-4295(02)02296-3.View ArticlePubMed
- Litwin MS, McNaughton-Collins M, Fowler FJ, Nickel JC, Calhoun EA, Pontari MA, Alexander RB, Farrar JT, O'Leary MP: The National Institutes of Health chronic prostatitis symptom index: Development and validation of a new outcome measure. J Urol. 1999, 162: 369-375. 10.1016/S0022-5347(05)68562-X.View ArticlePubMed
- Propert KJ, Alexander RB, Nickel JC, Kusek JW, Litwin MS, Landis JR, Nyberg LM, Schaeffer AJ, Chronic Prostatitis Collaborative Research Network: Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology. 2002, 59: 870-876. 10.1016/S0090-4295(02)01601-1.View ArticlePubMed
- Casey J: Changes in symptoms and quality of life in patients with chronic prostatitis. Nat Clin Pract Urol. 2006, 3 (5): 240-1. 10.1038/ncpuro0471.View Article
- Propert KJ, McNaughton-Collins M, Leiby BE, O'Leary MP, Kusek JW, Litwin MS, Chronic Prostatitis Collaborative Research Network: A prospective study of symptoms and quality of life in men with chronic prostatitis/chronic pelvic pain syndrome: the National Institutes of Health Chronic Prostatitis Cohort study. J Urol. 2006, 175 (2): 619-23. 10.1016/S0022-5347(05)00233-8. discussion 623View ArticlePubMed
- Ku JH, Kim SW, Paick JS: Quality of life and psychological factors in chronic prostatitis/chronic pelvic pain syndrome. Urology. 2005, 66 (4): 693-701. 10.1016/j.urology.2005.04.050.View ArticlePubMed
- Tripp DA, Curtis Nickel J, Landis JR, Wang YL, Knauss JS, CPCRN Study Group: Predictors of quality of life and pain in chronic prostatitis/chronic pelvic pain syndrome: findings from the National Institutes of Health Chronic Prostatitis Cohort Study. BJU Int. 2004, 94 (9): 1279-82. 10.1111/j.1464-410X.2004.05157.x.View ArticlePubMed
- Coeytaux RR, Kaufman JS, Kaptchuk TJ, Chen W, Miller WC, Callahan LF, Mann JD: A randomized, controlled trial of acupuncture for chronic daily headache. Headache. 2005, 45: 1113-1123. 10.1111/j.1526-4610.2005.00235.x.View ArticlePubMed
- David J, Townsend S, Sathanathan R, Kriss S, Dore CJ: The effect of acupuncture on patients with rheumatoid arthritis: a randomized, placebo-controlled cross-over study. Rheumatology. 1999, 38: 864-869. 10.1093/rheumatology/38.9.864.View ArticlePubMed
- Chen Y, Song B, Jin XY, Xiong EQ, Zhang JH: Possible mechanism of referred pain in the perineum and pelvis associated with the prostate in rats. J Urol. 2005, 174: 2405-2408. 10.1097/01.ju.0000180421.90260.65.View ArticlePubMed
- Shahed AR, Shoskes DA: Correlation of beta-endorphin and prostaglandin E2 levels in prostatic fluid of patients with chronic prostatitis with diagnosis and treatment response. J Urol. 2001, 166: 1738-1741. 10.1016/S0022-5347(05)65664-9.View ArticlePubMed
- Nadler RB, Koch AE, Calhoun EA, Campbell PL, Pruden DL, Bennett CL, Yarnold PR, Schaeffer AJ: IL-1beta and TNF-alpha in prostatic secretions are indicators in the evaluation of men with chronic prostatitis. J Urol. 2000, 164: 214-218. 10.1016/S0022-5347(05)67497-6.View ArticlePubMed
- Zijlstra FJ, van den Berg-de Lange I, Huygen FJ, Klein J: Anti-inflammatory actions of acupuncture. Mediators Inflamm. 2003, 12: 59-69. 10.1080/0962935031000114943.PubMed CentralView ArticlePubMed
- Alexander RB, Propert KJ, Schaeffer AJ, Landis JR, Nickel JC, O'Leary MP, Pontari MA, McNaughton-Collins M, Shoskes DA, Comiter CV, Datta NS, Fowler JE, Nadler RB, Zeitlin SI, Knauss JS, Wang Y, Kusek JW, Nyberg LM, Litwin MS, Chronic Prostatitis Collaborative Research Network: Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double-blind trial. Ann Intern Med. 2004, 141: 581-589.View ArticlePubMed
- Habermacher GM, Chason JT, Schaeffer AJ: Prostatitis/Chronic Pelvic Pain Syndrome. Annu Rev Med. 2006, 57: 195-206. 10.1146/annurev.med.57.011205.135654.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.